Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Total Non-Current Liabilities (2023 - 2025)

Guardian Pharmacy Services (GRDN) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $190.7 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 13.9% to $190.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $190.7 million through Dec 2025, up 13.9% year-over-year, with the annual reading at $190.7 million for FY2025, 13.9% up from the prior year.
  • Total Non-Current Liabilities hit $190.7 million in Q4 2025 for Guardian Pharmacy Services, up from $189.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $210.8 million in Q3 2024 to a low of $167.1 million in Q1 2025.
  • Historically, Total Non-Current Liabilities has averaged $182.2 million across 3 years, with a median of $179.8 million in 2023.
  • Biggest YoY gain for Total Non-Current Liabilities was 13.9% in 2025; the steepest drop was 10.2% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $179.8 million in 2023, then dropped by 6.89% to $167.4 million in 2024, then grew by 13.9% to $190.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for GRDN at $190.7 million in Q4 2025, $189.3 million in Q3 2025, and $170.5 million in Q2 2025.